Previous close | 13.66 |
Open | 17.08 |
Bid | 16.06 x 1300 |
Ask | 16.13 x 200 |
Day's range | 14.87 - 17.99 |
52-week range | 6.46 - 35.67 |
Volume | |
Avg. volume | 3,466,144 |
Market cap | 2.488B |
Beta (5Y monthly) | 2.32 |
PE ratio (TTM) | 178.89 |
EPS (TTM) | 0.09 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 30.43 |
Comprehensive Analysis of TG Therapeutics' First Quarter Financial Performance
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -133.33% and 15.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Compan